Brief: Lyell Immunopharma Announces Initiation Of Patient Dosing In First-Of-Its-Kind Phase 3 Car T-Cell Clinical Trial
12/02/2026 13:02
Feb 12 (Reuters) - Lyell Immunopharma Inc LYEL.O: LYELL IMMUNOPHARMA ANNOUNCES INITIATION OF PATIENT DOSING IN FIRST-OF-ITS-KIND PHASE 3 HEAD-TO-HEAD CAR T-CELL CLINICAL TRIAL IN AGGRESSIVE LARGE B-CELL LYMPHOMA LYELL IMMUNOPHARMA INC - BLA SUBMISSION EXPECTED IN 2027 Source text: ID:nGNX4J0klb Further company coverage: LYEL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma